SelSym Biotech’s Breakthrough: Synthetic Platelets to Control Bleeding
SelSym Biotech, a startup pioneering in biotechnology, is on a mission to transform hemostasis with its groundbreaking development of synthetic platelets. Traditional platelets, essential for clotting and stopping bleeding, are in perpetual short supply due to their short shelf life. Recognizing this critical challenge, SelSym Biotech has unveiled a revolutionary solution: synthetic platelets.
Led by Ashley Brown, Ph.D., a biomedical engineer at North Carolina State University (NCSU), SelSym Biotech’s research team has developed tiny bits of ultra-soft hydrogel, termed platelet-like particles (PLPs), equipped with antibodies that bind directly to fibrin, a protein found at the wound site. These PLPs mimic the function of natural platelets, effectively stopping bleeding when they come into contact with fibrin.
The potential of SelSym’s synthetic platelets extends beyond addressing donor shortages. Unlike natural platelets, which have a short shelf life and require specific storage conditions, PLPs offer a longer shelf life and can be stored at room temperature, making them easier to transport and distribute, especially in remote or challenging-to-reach locations.
SelSym’s approach minimizes the risk of off-target blood clot formation, ensuring safety and efficacy in clinical applications. Promising results from studies conducted in mice, rats, and pigs demonstrate the effectiveness of PLPs in stopping trauma-induced bleeding without adverse effects.
With support from grants and ongoing research collaborations, SelSym Biotech is advancing towards clinical trials, aiming to translate its innovative technology into practical solutions for preventing unnecessary deaths due to uncontrolled bleeding.
SelSym Biotech’s journey exemplifies a commitment to overcoming critical challenges in medicine, offering hope for improved clinical outcomes and transforming the landscape of hemostasis with synthetic platelets.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
